Literature DB >> 35860821

Characteristics and Prognostic Factors of Venous Thromboembolism in Cancer Patients.

Hajime Tsuyuki1,2, Naoto Yamamoto1, Naoki Unno1,2, Kazunori Inuzuka2, Masaki Sano2, Kazuto Katahashi2, Tatsuro Yata2, Takafumi Kayama2, Yuta Yamanaka2, Yusuke Endo2, Hiroya Takeuchi2.   

Abstract

Background: Improving the prognosis of patients with malignant tumors is increasing the number of patients who develop venous thromboembolism. We examined the characteristics and prognostic factors of VTE patients with cancer.
Methods: We diagnosed 725 VTE patients from April 2005 to March 2018. There were 322 cancer associated patients (CAT) and 403 non-cancer associated patients (nonCAT). We examined characteristics and prognostic factors of VTE in CAT patients.
Results: There were 156 women and 166 men in CAT, and 132 women and 271 men in nonCAT. There was no significant difference in the location of proximal portion of thrombus. When locations were divided into left leg, right leg, and bilateral legs, bilateral cases were more common in CAT group. Comparing the overall survival after VTE diagnosis in the CAT group, the prognosis was poor in patients with high D-dimer level (≧6 µg/mL) along with cancer metastasis and recurrence. Conclusions: Various VTE factors predict prognosis in CAT patients, and CAT is important in the treatment of cancer patients. (This is secondary publication from Jpn J Phlebol 2020; 31(3): 153-159.).
© 2022 The Editorial Committee of Annals of Vascular Diseases.

Entities:  

Keywords:  cancer-associated thrombosis; deep vein thrombosis; pulmonary thromboembolism; venous thromboembolism

Year:  2022        PMID: 35860821      PMCID: PMC9257382          DOI: 10.3400/avd.oa.22-00036

Source DB:  PubMed          Journal:  Ann Vasc Dis        ISSN: 1881-641X


  22 in total

Review 1.  Does this patient have deep vein thrombosis?

Authors:  Philip S Wells; Carolyn Owen; Steve Doucette; Dean Fergusson; Huyen Tran
Journal:  JAMA       Date:  2006-01-11       Impact factor: 56.272

2.  Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.

Authors:  Gary H Lyman; Kari Bohlke; Alok A Khorana; Nicole M Kuderer; Agnes Y Lee; Juan Ignacio Arcelus; Edward P Balaban; Jeffrey M Clarke; Christopher R Flowers; Charles W Francis; Leigh E Gates; Ajay K Kakkar; Nigel S Key; Mark N Levine; Howard A Liebman; Margaret A Tempero; Sandra L Wong; Mark R Somerfield; Anna Falanga
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

3.  Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study).

Authors:  Jeffrey I Zwicker; Howard A Liebman; Kenneth A Bauer; Thomas Caughey; Federico Campigotto; Rachel Rosovsky; Simon Mantha; Craig M Kessler; Jonathan Eneman; Vidya Raghavan; Heinz-Joseph Lenz; Andrea Bullock; Elizabeth Buchbinder; Donna Neuberg; Bruce Furie
Journal:  Br J Haematol       Date:  2012-12-13       Impact factor: 6.998

4.  Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry.

Authors:  Silvy Laporte; Patrick Mismetti; Hervé Décousus; Fernando Uresandi; Remedios Otero; Jose Luis Lobo; Manuel Monreal
Journal:  Circulation       Date:  2008-03-17       Impact factor: 29.690

Review 5.  Venous thromboembolism and prognosis in cancer.

Authors:  Alok A Khorana
Journal:  Thromb Res       Date:  2010-01-25       Impact factor: 3.944

6.  Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis.

Authors:  R Seitz; N Rappe; M Kraus; A Immel; M Wolf; M Maasberg; R Egbring; R Pfab; K Havemann
Journal:  Blood Coagul Fibrinolysis       Date:  1993-04       Impact factor: 1.276

7.  Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases.

Authors:  Alex J Walker; Tim R Card; Joe West; Colin Crooks; Matthew J Grainge
Journal:  Eur J Cancer       Date:  2012-11-09       Impact factor: 9.162

Review 8.  The epidemiology of venous thromboembolism.

Authors:  John A Heit; Frederick A Spencer; Richard H White
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

9.  Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.

Authors:  Giancarlo Agnelli; Cecilia Becattini; Guy Meyer; Andres Muñoz; Menno V Huisman; Jean M Connors; Alexander Cohen; Rupert Bauersachs; Benjamin Brenner; Adam Torbicki; Maria R Sueiro; Catherine Lambert; Gualberto Gussoni; Mauro Campanini; Andrea Fontanella; Giorgio Vescovo; Melina Verso
Journal:  N Engl J Med       Date:  2020-03-29       Impact factor: 91.245

10.  Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

Authors:  Annie M Young; Andrea Marshall; Jenny Thirlwall; Oliver Chapman; Anand Lokare; Catherine Hill; Danielle Hale; Janet A Dunn; Gary H Lyman; Charles Hutchinson; Peter MacCallum; Ajay Kakkar; F D Richard Hobbs; Stavros Petrou; Jeremy Dale; Christopher J Poole; Anthony Maraveyas; Mark Levine
Journal:  J Clin Oncol       Date:  2018-05-10       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.